+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05389293

Phase 2 Study of Mosunetuzumab Alone or With Zanubrutinib for Treating Newly Diagnosed Follicular Lymphoma Needing Systemic Therapy

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-10

152

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating mosunetuzumab alone or combined with zanubrutinib as treatments for people newly diagnosed with follicular lymphoma who have not yet received any therapy. This phase 2, open-label, multicenter study aims to understand if mosunetuzumab, with or without zanubrutinib, is an effective option for patients needing systemic therapy for this type of lymphoma. The study will enroll an initial 53 participants and plans to expand by an additional 23 people. Participants will receive mosunetuzumab through a subcutaneous step-up dosing schedule during the first cycle, followed by regular doses every three weeks. Those in the combination group will also take zanubrutinib continuously for 12 months, starting either shortly before or during the treatment cycles. Treatment duration varies based on response those achieving complete response will stop after about six months, while others with partial response may continue for up to twelve months. Patients with stable or progressive disease will discontinue and receive other care as determined by their doctor. Throughout the study, participants will undergo tumor biopsies before and after starting treatment to monitor effects. Researchers will assess response rates up to one year and overall response over three years. Safety and treatment impact are monitored through clinical evaluations and laboratory tests, with ongoing follow-up planned until the studys completion in late 2027. Participants involvement includes regular visits for treatment administration, assessments, and sample collections according to the study schedule.

CONDITIONS

Brief Title

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Research Team

L

Lorenzo Falchi, MD

G

Gilles Salles, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here